Clinical Trials Logo

Clinical Trial Summary

Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04842513
Study type Interventional
Source University Hospital Tuebingen
Contact Ghazaleh Tabatabai, Prof
Phone +497071/29-83269
Email ghazaleh.tabatabai@uni-tuebingen.de
Status Recruiting
Phase Phase 1
Start date May 3, 2021
Completion date August 3, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03657576 - Trial of C134 in Patients With Recurrent GBM Phase 1
Recruiting NCT05685004 - Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Phase 2/Phase 3
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Completed NCT02474966 - Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study Phase 2
Active, not recruiting NCT02137759 - MRSI to Predict Response to RT/TMZ ± Belinostat in GBM Phase 2
Enrolling by invitation NCT03170141 - Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme Phase 1
Recruiting NCT04869449 - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas Early Phase 1
Recruiting NCT03633552 - Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Phase 3
Not yet recruiting NCT05095441 - A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma Phase 1
Completed NCT00003456 - Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme Phase 2
Completed NCT03047473 - Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme Phase 2
Enrolling by invitation NCT05116137 - The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors N/A
Recruiting NCT05627323 - CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma Phase 1
Active, not recruiting NCT04968366 - Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery Phase 1
Suspended NCT04222309 - Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) Phase 1
Not yet recruiting NCT06186440 - Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma Phase 1/Phase 2
Recruiting NCT06273176 - The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)